ERCC1核苷酸多态性C118T与中晚期宫颈癌患者顺铂耐药的相关性

摘要

目的 探究ERCC1核苷酸多态性C118T与中晚期宫颈癌患者顺铂耐药间的关系.方法 统计诊治的102例中晚期宫颈癌患者顺铂化疗疗效, 同时检测患者外周血ERCC1核苷酸多态性C118T比例, 将完全缓解+部分缓解定义为化疗敏感组;疾病进展+肿瘤稳定定义为化疗耐药组.比较该多态性与宫颈癌顺铂耐药间的关系.结果 纯合子CC型的基因显著存在于化疗敏感组(65％vs18％)(P ＜0.05);两组间杂合子TC型基因分布差异无统计学意义(P＞ 0.05);而纯合子TT型基因显著存在于化疗耐药组(67％vs25％)(P ＜0.05).化疗耐药组T等位基因频率显著高于化疗敏感组(74％vs30％)(P ＜0.05);与化疗敏感组相比, TT及TC基因型显著存在于化疗耐药组(OR=8.438, 95％CI=3.061～23.256);化疗耐药组T等位基因频率显著高于化疗敏感组(OR=6.819, 95％CI=3.519～13.214).结论 ERCC1核苷酸多态性C118T与中晚期宫颈癌患者顺铂化疗耐药间具有显著联系.%Objective To investigate the correlation between ERCC1 polymorphism C118T and cisplatin resistance in patients with advanced cervical cancer. Methods A total of 102 patients with advanced cervical cancer undergoing cisplatin chemotherapy were recruited. We detected the ERCC1 polymorphism C118T in peripheral blood and collected the follow-up data in these patients. The correlation between ERCC1 polymorphism C118T and cisplatin resistance in advanced cervical cancer was analyzed. Results The homozygous CC genotype was significant higher in chemotherapy sensitive group comparing to the chemotherapy resistant group(65％ vs. 18％, P ＜ 0.05). The distribution of heterozygous TC genotype showed no significant difference in these two groups, while the homozygous TT genotype was significant higher in chemotherapy resistant group(67％ vs. 25％, P ＜ 0.05). The frequency of allele C was significantly higher in chemotherapy resistant group than it in chemotherapy sensitive group(77％ vs. 29％, P ＜ 0.05). At the same time, patients with CC genotype was significantly less in chemotherapy resistant group(OR = 8.438, 95％ CI = 3.061-23.256)compared to the chemotherapy sensitive group. The frequency of allele T was significantly higher in chemotherapy resistant group than that in chemotherapy sensitive group(OR = 6.819, 95％ CI = 3.519-13.214). Conclusion ERCC1 polymorphism C118T is associated to the cisplatin resistance in patients with advanced cervical cancer.